EOLS - Evolus enrolls 1st patient in study of 'extra-strength' dose of Botox rival Jeuveau

Medical aesthetics company Evolus (NASDAQ:EOLS) enrolled its first patient in a phase 2 study evaluating an "extra-strength" dose for extended duration of Jeuveau, its flagship neurotoxin drug to treat forehead wrinkles and frown lines. Jeuveau competes with Botox, made by AbbVie's unit Allergan. The double blind, randomized study will follow 150 patients for up to 12 months. Study will consist of two active controls - the currently approved 20 units of Jeuveau and 20 units of Botox Cosmetic which will be compared to 40 units of "extra-strength" Jeuveau. “While many of our customers believe the original strength, 20-unit dose of Jeuveau will comprise a majority of their use, clinicians have voiced the desire for an ‘extra-strength’ dose option as well," said Evolus CEO David Moatazedi. Evolus expects to complete the study in H1 2023.

For further details see:

Evolus enrolls 1st patient in study of 'extra-strength' dose of Botox rival Jeuveau